TheraGenetics Ltd, which produces gene-based tests for establishing the likelihood of a patient responding to a drug or of experiencing side effects, has appointed Heiner Dreismann as chairman. Dr. Dreismann most recently served as President and Chief Executive Officer of Roche Molecular Systems, Inc. (RMS), the division of Hoffmann-La Roche Ltd that pioneered clinical molecular diagnostics.
